| 000 | 01673 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250518043855.0 | ||
| 264 | 0 | _c20191223 | |
| 008 | 201912s 0 0 eng d | ||
| 022 | _a1471-2407 | ||
| 024 | 7 |
_a10.1186/s12885-019-5788-9 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKümler, Iben | |
| 245 | 0 | 0 |
_aTwo open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene. _h[electronic resource] |
| 260 |
_bBMC cancer _cJun 2019 |
||
| 300 |
_a573 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aBiomarkers, Pharmacological |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdiagnosis |
| 650 | 0 | 4 |
_aDNA Topoisomerases, Type I _xgenetics |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIrinotecan _xtherapeutic use |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aReceptor, ErbB-2 _xmetabolism |
| 650 | 0 | 4 |
_aTopoisomerase I Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aTrastuzumab _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aBalslev, Eva | |
| 700 | 1 | _aStenvang, Jan | |
| 700 | 1 | _aBrünner, Nils | |
| 700 | 1 | _aEjlertsen, Bent | |
| 700 | 1 | _aJakobsen, Erik Hugger | |
| 700 | 1 | _aNielsen, Dorte Lisbet | |
| 773 | 0 |
_tBMC cancer _gvol. 19 _gno. 1 _gp. 573 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s12885-019-5788-9 _zAvailable from publisher's website |
| 999 |
_c29795309 _d29795309 |
||